Abstract Number: 88 • Pediatric Rheumatology Symposium 2017
Clinical Features and Frequency of Biologic use in Patients with Juvenile Dermatomyositis-associated Calcinosis
Background/Purpose: Calcinosis develops in an estimated 40% of patients with Juvenile Dermatomyositis (JDM). Conflicting studies have not definitively identified actionable risk factors or demonstrated that…Abstract Number: 89 • Pediatric Rheumatology Symposium 2017
Abatacept as Adjunct Therapy for the Calcinosis of Juvenile Dermatomyositis: A Single-Center Experience
Background/Purpose: Juvenile dermatomyositis (JDMS) is an autoimmune inflammatory myopathy which primarily manifests with skin, muscle, and blood vessel involvement. Dystrophic calcification or calcinosis has been…Abstract Number: 2065 • ACR/ARHP Annual Meeting 2013
The Prevalence and Clinical Usefulness Of Anti-NXP-2 Autoantibodies In Chinese Patients With Idiopathic Inflammatory Myopathies
Background/Purpose: To determine the sera levels of anti-NXP-2 antibodies and their clinical association in Chinese patients with idiopathic inflammatory myopathies(IIM). Methods: Sera from 198 Chinese…Abstract Number: 301 • ACR/ARHP Annual Meeting 2012
Decreased Frequency of Dystrophic Calcifications in Children with Juvenile Dermatomyositis: A 10-Year Study
Background/Purpose: In Juvenile Dermatomyositis (JDM), dystrophic calcifications, associated with increased morbidity and mortality, have been reported for 20-30% of patients. There are few laboratory indicators…
ACR Meeting Abstracts